Karl is co-founder of Aglaia BioMedical Ventures. He holds an MBA from the University of Georgia (USA), following his studies at The Netherlands School of Business, Nijenrode. Before starting up Aglaia, he was involved in the founding, restructuring and funding of multiple technology-driven companies. In 1995, he founded Entity Holding B.V., a venture company focusing on early-stage companies. Karl serves at the board of a number of life sciences companies.
ISA Pharmaceuticals and Regeneron Announce Strategic Immuno-Oncology Collaboration
Cristal Therapeutics awarded €2.5 million Horizon 2020 grant to advance its CriPec®-docetaxel through Phase 2 trials